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imaging within 12 hours of symptoms. Clinical and epidemiologic data,
lesion volumes, apparent diffusion coefficient maps, profusion maps, and
cerebral blood flow and cerebral blood flow values were compared in
patients without and with prodromal TIAs.
Among the 65 patients with territorial strokes, 16 had prodromal TIAs.
In the patients with TIAs prior to stroke, the TIA occurred within 4 weeks of
the stroke in 10 patients and more than 4 weeks from the stroke in 6 patients.
Final infarct size was significantly less in stroke patients with prodromal TIAs
than in those without TIAs (P  .014). Differences in infarct volume were
even more pronounced between patients without prodromal TIAs and
patients whose TIAs occurred fewer than 4 weeks from the onset of stroke
(P  .002). Patients with prodromal TIAs had milder clinical deficits than
those without TIAs. Multiple regression analysis indicated that the only
analyzed parameter predictive of small final infarct size was prodromal TIAs.
Comment: This study argues for an intrinsic neuroprotective effect of
TIAs in patients with subsequent stroke that is independent of changes in
blood flow and collateral development. The mechanism of this neuropro-
tection is unknown, but the data suggest a new line of research with regard
to inducing tolerance of neural tissues to ischemia.
Thrombogenesis and endothelial damage/dysfunction in peripheral
artery disease: relationship to ethnicity and disease severity
Mankin AJ, Chung NAY, Silverman SH, Lip GYH. Thromb Res 2003;11:
221-6.
Conclusions: Peripheral arterial disease (PAD) is associated with a
prothrombotic state characterized by increased levels of markers of endo-
thelial function/damage, platelet activation, and thrombosis, which do not
differ with respect to ethnicity. The only prothrombotic marker related to
severity of PAD is plasma fibrinogen levels.
Summary: The authors investigated markers of platelet activation and
endothelial function in 234 patients (80% white, 7% Indo-Asian, 13%
Afro-Caribbean) with PAD (ankle-brachial index 0.8) and 50 control
patients without evidence of PAD. Levels of soluble P-selectin (a marker of
platelet activation), vonWillebrand factor (an index of endothelial function/
damage), tissue factor, and fibrinogen were correlated with disease severity
and ethnicity.
All of the markers studied were higher in patients with PAD versus
controls without PAD (P .05). There was no difference in the level of any
of the markers among the ethnic groups studied. Patients with ischemic rest
pain had higher levels of plasma fibrinogen (P .001). No other prothrom-
botic markers were higher in the rest pain group. There was an inverse
correlation between fibrinogen and the ankle-brachial index (Speerman, r
-0.178; P  .009).
Comment: A frequent end point of atherosclerosis is thrombosis. Data
from this study suggest that patients with atherosclerosis may be predisposed
to thrombosis through a prothrombotic state associated with PAD. The
clinical relevance of a generalized prothrombotic state in patients with
atherosclerosis is, however, unclear, as disease severity appeared to correlate
only with fibrinogen levels.
A cross-sectional study evaluating post-thrombotic syndrome in chil-
dren
Kuhles S, Koloshuk B, Marzinotto V, et al. Thromb Res 2003;111:227-33.
Conclusion: Post-thrombotic syndrome (PTS) is a clinically significant
disease in children with previous upper extremity and lower extremity deep
venous thrombosis (DVT).
Summary: The authors performed a cross-sectional study in 151
pediatric patients with objectively confirmed upper and/or lower extremity
DVT. All subjects were assessed by using a standardized PTS score to
determine the clinical characteristics, incidence, and predictors of PTS in
children. Severity of PTS was classified as absent, mild, moderate, or severe
according to the scoring system.
All patients’ DVT was diagnosed by objective testing. Fifty-three (35%)
of children had upper extremity DVT; 91 (59%) had lower extremity DVT.
Anticoagulant therapy was used in 95% with a median duration of 3 months.
Age was the only demographic that differed between children who devel-
oped PTS after DVT and those who did not develop PTS after DVT: the
PTS children were slightly older than children with DVT and no PTS.
PTS was present in 63% of children overall. There was no difference in
the children with and without PTS with respect to upper extremity or lower
extremity DVT. According to the severity scoring system, PTS was classified
as mild in 83%, moderate in 17%. No patients had severe PTS. The most
common objective clinical presentation was increased limb circumference
(71%) and the presence of a visible collateral circulation (53%). The most
common clinical complaint was swelling (43%).
Forty-one percent of children had complete resolution of DVT. Chil-
dren with no resolution or extension of DVT, as assessed by objective
testing, were 4 times more likely to have PTS than children with DVT
resolution. For every additional vessel involved in the initial DVT, the
likelihood for a higher PTS score increased by a factor of 2.1. For every year
following the initial DVT, the likelihood for having a higher PTS score
increased by a factor of 1.2.
Comment: This is one of the first articles detailing the risk and
magnitude of the late effects of DVT in children and indicates the post-
thrombotic syndrome is a clinically detectable disease in children but does
not apparently lead to all that much disability. The fact there was no
difference in the frequency and magnitude of PTS between children with
upper and lower extremity DVT may reflect that the etiologies of upper and
lower extremity DVT in children are both generally catheter related. This is
in contrast to adults, where upper extremity DVT is largely catheter related
and of little late clinical significance, whereas lower extremity DVT is not
catheter related and often has late clinical significance.
Stent-graft repair of penetrating atherosclerotic ulcers in the descend-
ing thoracic aorta: mid-term results
Demers P, Claire DC, Mitchell RS, et al. Annals Thoracic Surgery 2004;77:
81-6.
Conclusions: Stent-graft repair of penetrating atherosclerotic ulcers in
the descending thoracic aorta has a high initial success rate. However,
freedom from treatment failure is only 65% at 5 years. Both female sex and
larger aortic diameters were risk factors for treatment failure.
Summary: Between 1993 and 2000, endovascular repair of penetrat-
ing atherosclerotic ulcers (PAUs), with both custom fabricated and com-
mercial stent grafts, was performed in 26 patients. The mean age was 70
years, and 6 patients had evidence of rupture. Fourteen patients (54%) were
not considered candidates for open surgical repair. Follow-up was complete
in all patients and averaged 51 months, with a maximum 114 months.
Three of the 26 patients died within 30 days and 2 had an early type I
endoleak. The primary success rate for placement of a descending aortic stent
graft was 92%. Survival at 1, 3, and 5 years was 85%, 76%, and 70%. Freedom
from treatment failure was 81%, 71%, and 65% at 1, 3, and 5 years,
respectively. Multivariable analysis indicated predictors of treatment failure
were increasing aortic diameter (hazard ratio: 1.1 [per millimeter above the
mean value]; P  .01) and female sex (hazard ratio 5.5; P  .09).
Comment: As with endovascular repair of abdominal aortic aneurysms,
endovascular repair of the descending thoracic aorta appears to be a techni-
cally possible, but not curative, treatment. The data suggests the devices
currently available for the thoracic aorta are, in terms of effectiveness and
clinical durability, still inferior to those available for treatment of infrarenal
abdominal aortic aneurysms.
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